Celgene's CAR-T Leadership Goals Advance At ASH 2017

Celgene's partnership strategy paid off at ASH with positive results for two CAR-T therapies in development with bluebird bio and Juno. The company is pursuing first- and best-in-class opportunities with the goal of becoming a leader in the CAR-T field.

T-cells attacking cancer_1200x675

More from Clinical Trials

More from R&D